Quantcast

Latest Celsion Corporation Stories

2014-10-07 16:27:14

LAWRENCEVILLE, N.J., Oct. 7, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced that the Board of Directors has appointed Michael H. Tardugno, the Company's President and CEO, to the additional position of Executive Chairman of the Board. Mr. Tardugno's appointment is consistent with the Board's previously established succession plan and follows the passing of Max E. Link, Ph.D. which was announced earlier today. At the direction of Mr. Tardugno, the Nominating...

2014-10-07 16:27:09

LAWRENCEVILLE, N.J., Oct. 7, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) is saddened to announce the passing of Max E. Link, Ph.D., a Director and the Chairman of the Board of Directors of the Company. Dr. Link passed away unexpectedly at the age of 74. Michael H. Tardugno, President and Chief Executive Officer of Celsion, stated, "Max was a pillar in the pharmaceutical industry - a visionary who believed in the transformative power of science to positively impact human...

2014-09-08 08:30:50

Highly Attended Celsion-Sponsored Symposium on Current Concepts for Treating Intermediate HCC included: New Paradigm in Staging HCC Patients; Phase III Studies in HCC; and Advances in Image Guided Radiofrequency Ablation LAWRENCEVILLE, N.J., Sept. 8, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced highlights from three presentations by three of the world's leading liver cancer experts and principal investigators for the Company's...

2014-09-04 08:31:36

ThermoDox® Combined with Mild Local Hyperthermia is Safe and Produces Compelling Objective Local Responses in RCW Breast Cancer Patients LAWRENCEVILLE, N.J., Sept. 4, 2014 /PRNewswire/ -- September 4, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced that data from two Phase I studies on ThermoDox® in recurrent chest wall breast cancer were published in the International Journal of Hyperthermia. The article, titled "Two phase 1...

2014-09-02 08:30:12

Kyungpook National University Hospital in South Korea Treats the First Patient in the 14 Country, 100 Site Global Study LAWRENCEVILLE, N.J., Sept. 2, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), an oncology drug development company, today announced that the first patient has been enrolled in its pivotal Phase III OPTIMA Study of ThermoDox® in combination with optimized radiofrequency ablation (RFA) in patients with primary liver cancer, also known as hepatocellular...

2014-08-28 08:28:05

LAWRENCEVILLE, N.J., Aug. 28, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced that Michael H. Tardugno, Celsion's President and Chief Executive Officer, will be presenting at the Rodman & Renshaw 16th Annual Healthcare Conference on Tuesday, September 9(,), 2014 at 10:50 a.m. Eastern Time. The conference is being held at The New York Palace Hotel in New York City. A copy of the presentation will be available on...

2014-07-31 08:35:47

Conference Call on Thursday, August 7, 2014 LAWRENCEVILLE, N.J., July 31, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today that the Company will host a conference call to discuss its second quarter 2014 financial results at 11:00 a.m. EDT on Thursday, August 7, 2014. To participate in the call, interested parties may dial 1-800-533-7954 (Toll-Free/North America) or 1-785-830-1924 (International/Toll) and ask for the Celsion Corporation Second Quarter 2014...

2014-07-28 08:29:13

Latest Data Sweep from a 285 Patient Subgroup Shows An Impressive 57% Improvement in Overall Survival LAWRENCEVILLE, N.J., July 28, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) today announced updated results from its retrospective analysis of the Company's 701-patient HEAT Study of ThermoDox®, Celsion's proprietary heat-activated liposomal encapsulation of doxorubicin, in combination with radiofrequency ablation (RFA) in primary liver cancer, also known as...

2014-07-24 08:33:56

ThermoDox® Continues to Demonstrate Impressive Local Response Rate in Refractory Patients LAWRENCEVILLE, N.J., July 24, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN) announced today positive interim data from its ongoing open-label Phase 2 DIGNITY Trial of ThermoDox® in Recurrent Chest Wall Breast Cancer (RCWBC). The trial is designed to enroll 20 patients at several U.S. clinical sites and is evaluating ThermoDox in combination with mild hyperthermia. Of the 13 patients...

2014-07-15 08:28:34

Potential in Life Science Research Validates Newly Acquired Technology Platforms for the Delivery of Plasmid DNA and a Variety of RNA in Mammalian Cells LAWRENCEVILLE, N.J., July 15, 2014 /PRNewswire/ -- Celsion Corporation (NASDAQ: CLSN), a leading oncology drug development company, today announced initiation of sales of its proprietary reagent products for life science research. Celsion's reagent products are based on its newly acquired proprietary delivery platform technologies,...


Word of the Day
ramage
  • Boughs or branches.
  • Warbling of birds in trees.
Related